uniQure Company Overview, Contact Details & Competitors

Insights

Gathering insights about uniQure…

Similar companies to uniQure

uniQure Tech Stack

uniQure uses 8 technology products and services including Google Analytics, SAS, Craft CMS, and more. Explore uniQure's tech stack below.

Google Analytics
Analytics
SAS
Business Intelligence
Craft CMS
Content Management System
Microsoft 365
Email
Azure Active Directory
Identity And Access Management
Microsoft Active Directory
IT Infrastructure
ServiceNow
Miscellaneous
Buildout
Real Estate Marketing

Media & News

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.
Dec 15, 2024 | www.fool.com
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
Dec 11, 2024 | www.zacks.com
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~
Dec 10, 2024 | www.globenewswire.com
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nov 29, 2024 | www.zacks.com
What Makes uniQure (QURE) a New Buy Stock
uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nov 28, 2024 | www.zacks.com
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE).
Nov 21, 2024 | www.globenewswire.com
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 169.2% in uniQure (QURE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nov 08, 2024 | www.zacks.com

uniQure's Email Address Formats

uniQure uses at least 1 format(s):

uniQure Email Formats	Example	Percentage
F.Last@uniqure.com	J.Doe@uniqure.com	96%
Last.First@uniqure.com	Doe.John@uniqure.com	1%
First.Last@uniqure.com	John.Doe@uniqure.com	2%
First_Last@uniqure.com	John_Doe@uniqure.com	1%

Frequently Asked Questions

Where is uniQure's headquarters located?

uniQure's main headquarters is located at Paasheuvelweg 25a Amsterdam, 1105BP 1105BP NL. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is uniQure's phone number?

You can contact uniQure's main corporate office by phone at

+1-339-970-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is uniQure's stock symbol?

uniQure is a publicly traded company; the company's stock symbol is QURE.

What is uniQure's official website and social media links?

uniQure's official website is uniqure.com and has social profiles on LinkedIn.

How much revenue does uniQure generate?

As of December 2024, uniQure's annual revenue reached $750M.

What is uniQure's SIC code NAICS code?

uniQure's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does uniQure have currently?

As of December 2024, uniQure has approximately 501 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: M. K.Chief Medical Officer: W. A.Chief People And Culture Officer: E. B.. Explore uniQure's employee directory with LeadIQ.

What industry does uniQure belong to?

uniQure operates in the Biotechnology Research industry.

What technology does uniQure use?

uniQure's tech stack includes Google AnalyticsSASCraft CMSMicrosoft 365Azure Active DirectoryMicrosoft Active DirectoryServiceNowBuildout.

What is uniQure's email format?

uniQure's email format typically follows the pattern of . Find more uniQure email formats with LeadIQ.

How much funding has uniQure raised to date?

As of December 2024, uniQure has raised $150M in funding. The last funding round occurred on Mar 01, 2020 for $150M.

When was uniQure founded?

uniQure was founded in 1998.

Insights

Similar companies to uniQure

bluebird bio

Roche

AstraZeneca

Novartis

Pfizer

Vertex Pharmaceuticals

CRISPR Therapeutics

Sanofi

Amgen

Biogen

Editas Medicine

Sarepta Therapeutics

uniQure Tech Stack

Media & News

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet

What Makes uniQure (QURE) a New Buy Stock

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade

uniQure's Email Address Formats

Frequently Asked Questions

Where is uniQure's headquarters located?

What is uniQure's phone number?

What is uniQure's stock symbol?

What is uniQure's official website and social media links?

How much revenue does uniQure generate?

What is uniQure's SIC code NAICS code?

How many employees does uniQure have currently?

What industry does uniQure belong to?

What technology does uniQure use?

What is uniQure's email format?

How much funding has uniQure raised to date?

When was uniQure founded?

uniQure

Company Overview

Media & News

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?